Monitoring and Assessment of Circulating Tumor DNA in Cancers Using Ultrarapid Sensitivity as an Innovative Practice

Area of Science:

• Oncology
• Molecular Diagnostics
• Biotechnology

Background:

• Liquid biopsy using circulating tumor DNA (ctDNA) is a noninvasive method for real-time assessment of tumor burden, genetic heterogeneity, and treatment response.
• Low ctDNA concentrations (<0.1%) pose significant challenges for reliable detection, particularly in early-stage disease and minimal residual disease detection.

Purpose of the Study:

• To analyze innovative, ultrasensitive ctDNA assay technologies for cancer detection and monitoring.
• To explore future research and clinical applications of ctDNA assays in various cancers, including breast, colorectal, lung, lymphoid, and gastroesophageal cancers.
• To evaluate ctDNA's role in monitoring treatment response and detecting molecular recurrence.

Main Methods:

• Review and analysis of advanced ctDNA detection technologies, including structural variant (SV)-based assays, nanomaterial-based electrochemical sensors, and magnetic nano-electrode platforms.
• Investigation of fragment-enriched library preparation techniques to enhance ctDNA assay sensitivity.
• Exploration of emerging technologies such as multiplexed CRISPR-Cas ctDNA assays, microfluidic point-of-care (POC) devices, and AI-based error suppression methods.

Main Results:

• New technologies have improved ctDNA assay sensitivity to attomolar concentrations, enabling earlier detection of cancer recurrence (potentially >1 year before clinical evidence).
• These advancements offer significant opportunities for early cancer detection, monitoring treatment efficacy, and identifying molecular recurrence.
• Despite progress, widespread clinical adoption is hindered by pre-analytical and analytical variability, cost, and the need for large-scale prospective trials.

Conclusions:

• Innovative ultrasensitive ctDNA assays hold promise for revolutionizing cancer diagnostics and management.
• Future directions include integrating CRISPR-Cas systems, microfluidic POC devices, and AI for enhanced ctDNA detection.
• Addressing current barriers is crucial for realizing the full clinical potential of ctDNA liquid biopsies across multiple cancer types.